Dr. Nick Shubin joined NemaGen as their CEO in September of 2022 and leads NemaGen’s efforts to provide first-in-class therapies for people with mast cell-related diseases and pulmonary fibrosis. Prior to joining NemaGen, Dr. Shubin worked as a Business Development Manager and Applications Specialist for Quanterix for nearly 3 years, where he formed key collaborations and relationships with CROs and pharmaceutical companies in the region to help achieve sales goals. Nick also completed his postdoctoral studies at Seattle Children's Research Institute, where he published many articles related to understanding the roles of mast cells in homeostasis and disease.